A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
A phase 1/2 trial of HMBD-001, Docetaxel, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Hummingbird Bioscience, now recruiting.
Overview
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers is a phase 1/2 interventional study registered as NCT05910827 by Hummingbird Bioscience, with 398 participants planned, started 2024-02-05 and due to reach its primary completion in 2027-12-01. Interventions recorded: HMBD-001, Docetaxel, Cetuximab. Conditions listed: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAK129 Combination Therapy for Advanced Solid Tumors
Shares Cetuximab, Docetaxel, Head and neck squamous cell carcinoma, Small-cell lung cancer.
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer.
- TrialClinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.